HUM vs CLOV

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Aug 03, 2026

HUM

53.8
AI Score
VS
HUM Wins

CLOV

48.9
AI Score

Investment Advisor Scores

HUM

54score
Recommendation
HOLD

CLOV

49score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric HUM CLOV Winner
Revenue 749.19M 39.65B HUM
Net Income 27.33M 1.19B HUM
Net Margin 3.6% 3.0% CLOV
Operating Income 27.33M 1.75B HUM
ROE 8.1% 6.4% CLOV
ROA 3.9% 2.1% CLOV
Total Assets 697.73M 55.28B HUM
Current Ratio 1.33 1.77 HUM
Free Cash Flow 107.04M 1.13B HUM

Relative Price Performance (Last 90 Days)

HUM 1M: -7.1% · 3M: +57.8% CLOV 1M: -18.4% · 3M: +58.4%

Current Technical Phase

HUM

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 44

RSI (14): 44.1 · Price: $368.66

CLOV

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 45

RSI (14): 44.8 · Price: $4.29

Fundamentals Snapshot

Metric HUM CLOV
Market Cap
Forward P/E 22.7 43.3
Trailing P/E 34.4
Revenue (TTM)
Revenue Growth 0.3% 0.6%
Gross Margin 0.1% 0.2%
Operating Margin 0.0% 0.0%
EPS 10.59 -0.12
Dividend Yield 0.01%

Frequently Asked Questions

Based on our detailed analysis, HUM is currently the stronger investment candidate, winning 6 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.